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Immunogenicity and reactogenicity of primary vaccination with combined diphtheria–tetanus–acellular
pertussis–hepatitis B–inactivated poliovirus (DTPa–HBV–IPV) vaccine when co-administered with Haemophilus
influenzae (Hib) conjugate vaccine were assessed in 60 healthy infants. Infants received HBV vaccine at birth,
then DTPa–HBV–IPV and Hib vaccines at age 1.5 months, 3.5 months and 6 months. Blood samples were
collected before the first DTPa–HBV–IPV and Hib vaccine doses and 1 month after dose 3. Reactogenicity
was assessed using diary cards. One month after primary vaccination, all infants were seroprotected/
seropositive against all vaccine antigens evaluated. The poliovirus antigen could not be evaluated. The vac-
cines were well tolerated. No case of fever > 39.0°C was reported. No serious adverse events were consid-
ered related to vaccination. Primary vaccination with DTPa–HBV–IPV and Hib vaccines was immunogenic
and well tolerated. Combined vaccines, such as this pentavalent vaccine, minimize the number of injec-
tions and vaccination visits required to complete primary vaccination, and provide choice and flexibility
for physicians and vaccine providers.
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Hepatitis B infection affects about 2 billion indi-
viduals worldwide, of whom over 350 million
have chronic hepatitis. These individuals are at a
high risk of death from liver cancer and cirrhosis.1
Prevention of hepatitis infection through vaccina-
tion is the most effective means to prevent chronic
hepatitis B and its severe long-term consequences.
The World Health Organization has recommended
that all countries include hepatitis B vaccine in
their routine infant immunization programs.2
Combined vaccines have been developed to
reduce the complexity and discomfort associated
with administering multiple vaccines in different
vaccination schedules. In infancy, hepatitis B 
vaccine is frequently administered at birth, and 
1 month and 6 months of age. However, there is
evidence that vaccination against hepatitis B might
be just as effectively achieved using combined
vaccines, such as the pentavalent diphtheria–
tetanus–acellular pertussis–hepatitis B–inactivated
polio (DTPa–HBV–IPV) vaccine (Infanrix Penta;
GlaxoSmithKline Biologicals, Rixensart, Belgium).
This study assessed the immunogenicity and re-
actogenicity of the DTPa–HBV–IPV vaccine when
administered concomitantly with Haemophilus
influenzae (Hib) conjugate vaccine in a three-dose
primary vaccination course.
Patients and Methods
This was an open, single-group, single-center clini-
cal study conducted at the Department of Pedi-
atrics, National Taiwan University Hospital, Taipei,
Taiwan between September 18, 2000 and May 14,
2001 (Study ID: 217744/049; ClinicalTrials.gov
identifier: NCT00879827). The study was con-
ducted in accordance with good clinical practice,
local regulatory requirements, and the Declaration
of Helsinki. The study protocol, amendments and
consent forms were reviewed and approved by the
Ethics Committee of National Taiwan University
Hospital.
Healthy male or female infants aged between
6 and 8 weeks at the time of the first vaccination
were enrolled after obtaining written informed
consent from the child’s parent/guardian before
the performance of any study-specific procedures.
All infants received vaccination against hepatitis
B at birth, followed by primary vaccination with
DTPa–HBV–IPV and Hib vaccines at 1.5 months,
3.5 months and 6 months of age. Each 0.5-mL
dose of DTPa–HBV–IPV vaccine contained: 25 Lf
diphtheria toxoid, 10 Lf tetanus toxoid, 25 μg
pertussis toxoid (PT), 25 μg filamentous hemag-
glutinin (FHA), 8μg pertactin (PRN), 10μg recom-
binant hepatitis B surface antigen, 40 D antigen
units of poliovirus type 1 (Mahoney), 8 D anti-
gen units of poliovirus type 2 (MEF-1) and 32 D
antigen units of poliovirus type 3 (Saukett). The
conjugate Hib vaccine contained 10μg polyribosyl-
ribitol-phosphate (PRP) conjugated to tetanus
toxoid, and was supplied as a white freeze-dried
pellet in monodose vials, to be reconstituted before
use with a sterile saline diluent.
Blood samples were taken from all infants be-
fore the first vaccination at 1.5 months of age and
1 month after dose 3 at approximately 7 months of
age. Antibodies against each vaccine antigen were
measured using standard assays.3 A vaccine re-
sponse to pertussis antigens was defined as the ap-
pearance of antibodies (concentration≥ cut-off) in
initially seronegative subjects, or post-vaccination
antibody concentration≥pre-vaccination antibody
concentration in initially seropositive subjects.
The occurrence of specific local and general
symptoms after each dose was recorded on diary
cards. Other unsolicited symptoms were recorded
for 30 days (days 0–29) after each dose. Serious
adverse events were reported throughout the study
period. The investigator assessed possible causality
between symptoms and vaccination.
The antibody geometric mean concentration
was calculated by taking the anti-log of the mean
of the log concentration transformations. Sero-
positivity or seroprotection rates and geometric
mean concentration with 95% confidence intervals
were calculated for antibodies against diphtheria,
tetanus, pertussis, hepatitis B and PRP antigens.
The vaccine response for each pertussis antigen
was calculated at 1 month after the final vaccine
dose. The percentage of doses followed by local
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and general solicited symptoms within each 4-day
follow-up period was calculated with exact 95%
confidence intervals.
Results
Sixty infants were enrolled and completed the
study. The mean age of the infants in the total
vaccinated cohort at the time of the first DTPa–
HBV–IPV vaccine dose was 6.1 weeks (standard
deviation, ± 0.38 weeks). The male to female ratio
was 1.2 and all infants were of Asian origin.
Immunogenicity
A total of 55 infants met the eligibility criteria for
the according-to-protocol immunogenicity analy-
sis. Five infants were eliminated from the analysis
because they did not comply with the criteria stated
in the protocol; that is, age outside the specified
range (1 subject), and deviation from vaccina-
tion (1 subject) and blood sampling (3 subjects)
schedules.
The pre-vaccination seropositivity and sero-
protection rates ranged between 9.1% and 27.7%
for diphtheria, PT, PRN and PRP. Between 40.0%
and 42.2% of subjects were initially seropro-
tected against tetanus and hepatitis B, and 76.4%
had antibodies against FHA prior to the first 
vaccine dose.
One month after completion of the primary
vaccination course, all infants had seroprotective
antibody concentrations against diphtheria, teta-
nus, hepatitis B and Hib, and all subjects were sero-
positive for all three pertussis antigens (Table 1).
A total of 94.5% (52/55) of subjects reached the
higher anti-PRP antibody cut-off of 1.0 μg/mL. 
A vaccine response was observed in 100% of sub-
jects against PT (55/55) and FHA (54/54), and in
98.2% (54/55) of subjects against PRN. The im-
mune response to poliovirus antigens could not
be evaluated because laboratory investigations
identified chemical interference from the serum
samples in the poliovirus micro-neutralization
assay. The materials and methods used for the
collection of blood samples and preparation of
serum aliquots were the source of this interference,
which only affected the poliovirus neutralization
assay.
A secondary immunogenicity analysis on the
total vaccinated cohort was consistent with the
results of according-to-protocol cohort analysis.
Reactogenicity
Overall doses and pain were the most commonly
reported local symptoms and drowsiness and 
irritability were the most commonly reported
general symptoms after vaccination (Table 2).
Grade 3 local solicited symptoms tended to be
reported more frequently after dose 1 (up to 8.3%
Table 1. Antibody seroprotection/seropositivity rates and geometric mean antibody concentrations/titers 
1 month after primary vaccination with diphtheria–tetanus–acellular pertussis–hepatitis B–inactivated
poliovirus + Haemophilus influenzae type B vaccines at 1.5 months, 3.5 months and 6 months of
age (according to protocol cohort for immunogenicity)
Antibody n %SP 95%CI Value 95%CI
Diphtheria (IU/mL) 55 100 93.5–100 2.411 2.023–2.874
Tetanus (IU/mL) 55 100 93.5–100 3.062 2.428–3.861
Hepatitis B (mIU/mL) 41 100 91.4–100 773.5 488.8–1224.0
PT (EL.U/mL) 55 100 93.5–100 71.2 60.6–83.7
FHA (EL.U/mL) 54 100 93.4–100 289.6 248.0–338.1
PRN (EL.U/mL) 55 100 93.5–100 161.0 126.5–205.0
Anti-PRP (μg/mL) 55 100 93.5–100 11.409 7.939–16.395
n = number of children with available results; %SP = percentage of subjects seroprotected (antibody concentration ≥ 0.1 IU/mL for
diphtheria and tetanus, ≥ 10 mIU/mL for hepatitis B, and ≥ 0.15mg/mL for PRP) or seropositive (≥ 5 EL.U/mL for PT, FHA and PRN);
CI = confidence interval; PT = pertussis toxin; FHA = filamentous hemagglutinin; PRN = pertactin; PRP = polyribosyl-ribitol-phosphate.
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of doses) and less frequently after subsequent
doses (≤ 5.3%). Grade 3 irritability and loss of
appetite were reported in up to 5.3% of subjects
after each dose. Grade 3 drowsiness was reported
by no more than 1.7% of subjects after each dose.
No case of fever > 39.0°C was reported during
the study. The incidence of pain, loss of appetite
and fever tended to decrease with consecutive
vaccine doses.
Unsolicited symptoms were reported after
7.3% of doses over the vaccination course; none
were of grade 3 intensity. Three serious adverse
events were reported throughout the study period.
None were considered by the investigator to be
related to vaccination. No deaths occurred during
the study.
Discussion
Primary vaccination of Taiwanese infants with the
combined DTPa–HBV–IPV vaccine co-administered
with Hib conjugate vaccine was immunogenic and
well tolerated. All infants achieved seroprotective
antibody concentrations against hepatitis B after
completing the primary vaccination course. All
subjects had seroprotective antibody concentra-
tions against diphtheria, tetanus and Hib, and
were seropositive for antibodies against PT, FHA
and PRN after vaccination. The majority of in-
fants demonstrated a vaccine response against
each pertussis antigen.
The response to the poliovirus vaccine com-
ponent could not be satisfactorily examined in this
study due to abnormal serum toxicity that affected
laboratory testing. Serum toxicity refers to the pres-
ence of some component in the serum tested,
which induced the death of the Hep2 cells used in
the poliovirus neutralization assay, which resulted
in invalid results. Measurement by enzyme-linked
immunosorbent assay of serum antibodies against
other vaccine antigens was unaffected. The immu-
nogenicity of the IPV component of the DTPa–
HBV–IPV vaccine has been previously established
in other clinical trials of the vaccine in Europe,
Australia and the United States, with seroprotec-
tion rates against each poliovirus type exceeding
98%.3,4 In view of these results, it is unlikely that
Table 2. Incidence of local and general solicited symptoms after primary vaccination with diphtheria–
tetanus–acellular pertussis–hepatitis B–inactivated poliovirus + Haemophilus influenzae type B
vaccines at 1.5 months, 3.5 months and 6 months of age (total vaccinated cohort)
Dose 1 (n = 60) Dose 2 (n = 59) Dose 3 (n = 57)
Symptom Intensity
% 95% CI % 95% CI % 95% CI
Pain Any 63.3 49.9–75.4 62.7 49.1–75.0 56.1 42.4–69.3
Grade 3 6.7 1.8–16.2 1.7 0.0–9.1 3.5 0.4–12.1
Redness Any 53.3 40.0–66.3 50.8 37.5–64.1 54.4 40.7–67.6
> 20 mm 8.3 2.8–18.4 3.4 0.4–11.7 5.3 1.1–14.6
Swelling Any 43.3 30.6–56.8 35.6 23.6–49.1 47.7 34.0–61.0
> 20 mm 8.3 2.8–18.4 1.7 0.0–9.1 1.8 0.0–9.4
Drowsiness Any 60.0 46.5–72.4 54.2 40.8–67.3 36.8 24.4–50.7
Grade 3 1.7 0.0–8.9 1.7 0.0–9.1 0.0 0.0–6.3
Irritability Any 56.7 43.2–69.4 71.2 57.9–82.2 61.4 47.6–74.0
Grade 3 5.0 1.0–13.9 5.1 1.1–14.1 5.3 1.1–14.6
Loss of appetite Any 55.0 41.6–67.9 50.8 37.5–64.1 38.6 26.0–52.4
Grade 3 5.0 1.0–13.9 5.1 1.1–14.1 1.8 0.0–9.4
Fever (axillary) ≥ 37.5 °C 48.3 35.2–61.6 35.6 23.6–49.1 24.6 14.1–37.8
> 39.0 °C 0.0 0.0–6.0 0.0 0.0–6.1] 0.0 0.0–6.3
n = number of subjects with symptom sheets returned; % = percentage of subjects with the specified symptom; Grade 3: pain – cried
when the limb was moved/spontaneously painful; loss of appetite – not eating at all. For all other symptoms, grade 3=prevented normal
daily activities. CI = confidence interval.
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the infants in the present study failed to respond
to the poliovirus antigens.
The reactogenicity profile of the co-adminis-
tered DTPa–HBV–IPV and Hib vaccines was sat-
isfactory. The incidence of grade 3 symptoms was
within the range previously reported for these
vaccines.3,4 Grade 3 fever (> 39.0°C) was not re-
ported after any dose during the study. None of
the three serious adverse events that occurred
during the study were considered to be related to
the study vaccines.
The DTPa–HBV–IPV vaccine was licensed for
use in Europe in 2000 and in the United States in
2002. Clinical studies from Europe, the United
States and Australia have demonstrated that the
DTPa–HBV–IPV vaccine is immunogenic and
well-tolerated when used in a range of schedules,
and when co-administered with Hib conjugate
vaccines.3–10 The DTPa–HBV–IPV vaccine can also
be mixed with Hib conjugate vaccine and ad-
ministered as a single injection (Infanrix Hexa,
GlaxoSmithKline Biologicals).
Primary vaccination of infants from Taiwan
with DTPa–HBV–IPV induced seroprotective anti-
body responses against hepatitis B in all subjects.
Combined vaccines such as DTPa–HBV–IPV and
DTPa–HBV–IPV/Hib minimize the number of in-
jections and vaccination visits required to com-
plete primary vaccination, and provide choice and
flexibility for physicians and vaccine providers.
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